FDA Additional Information Requests: How to Respond to 510(k) Deficiency Letters (Complete Guide)
- Beng Ee Lim
- 2 days ago
- 13 min read
FDA Additional Information (AI) requests flag deficiencies in a 510(k) during substantive review and place the submission on hold. The submitter has 180 calendar days from the date of the AI Request to provide a complete response, and FDA states no extensions beyond 180 days are granted. The most common AI Request themes typically include substantial equivalence gaps, missing or unclear test evidence, incomplete device description, software documentation issues, biocompatibility rationale gaps, labeling problems, and risk management inconsistencies. Your best response strategy is: (1) identify the reviewer’s underlying concern, (2) answer every deficiency with traceable evidence, and (3) preserve your substantial equivalence narrative without introducing new claims you cannot support.
What Are FDA Additional Information Requests?
FDA Additional Information (AI) Requests are formal deficiency communications issued during the Substantive Review of a 510(k) when FDA needs clarification, additional evidence, or corrections to reach a substantial equivalence decision. If FDA sends an AI Request, the submission is placed on hold until FDA receives a complete response.
In recent MDUFA reporting discussions, AI requests have been common in first review cycles, sometimes around two-thirds of submissions in certain fiscal-year cohorts. The exact rate varies by year, device type, and submission quality.
Timeline and Process
When FDA issues an AI Request, the submission is placed on hold and the FDA review clock excludes that hold time when calculating FDA Days. The submitter has 180 calendar days from the date of the AI Request to submit a complete response. FDA states it must receive a complete response within 180 days and no extensions beyond 180 days are granted. If FDA does not receive a complete response within 180 days, the submission is considered withdrawn and deleted from FDA’s review system, and the sponsor must submit a new 510(k) to pursue clearance.
Types of AI Deficiencies
AI Requests can range from minor clarification items to major gaps that block a decision. A practical and commonly used way to think about the items inside an AI Request is major vs minor deficiencies, where major deficiencies are gaps critical to regulatory decision-making (missing testing, unclear methods, unsupported claims).
What Triggers Additional Information Requests
Common triggers include unclear or incomplete substantial equivalence rationale, missing or insufficient testing evidence, inconsistencies across sections (device description, indications, labeling, performance claims), software documentation gaps (when applicable), biocompatibility rationale gaps, and risk management inconsistencies.
International teams can be especially exposed when they convert CE Mark style technical documentation into a 510(k) without fully adapting to FDA’s substantial equivalence structure and FDA-recognized standards expectations. (This is a common pattern, but not a published FDA statistic.)
Understanding What FDA Really Wants: Surface Questions vs Underlying Concerns
FDA Additional Information (AI) questions often ask for a specific item, but the reviewer is usually testing a broader point: can FDA trust your evidence and your substantial equivalence story. Strong responses answer the surface question and also resolve the underlying concern that triggered it.
The gap between the question and the concern
Surface question: what FDA literally asked for.
Underlying concern: the safety, effectiveness, or equivalence doubt that makes the reviewer ask.
Example (biocompatibility)
FDA surface question: “Provide additional information regarding the biocompatibility testing performed for patient-contacting components.”
What FDA may really be checking:
Did you evaluate all patient-contacting materials and configurations, or only some?
Did your biological evaluation align with an ISO 10993-1 risk-management approach and FDA’s biocompatibility expectations for the contact type and duration?
Is there any reason to worry about material chemistry, residuals, or known sensitizers that would require stronger justification or additional evidence?
Did you match the device’s actual contact duration to the endpoints you addressed?
If you only paste test reports without addressing completeness, contact duration, and rationale, you often invite follow-up questions and delays.
How to identify the underlying concern
Re-read your original submission section
What did you provide, and what’s missing or ambiguous? AI Requests often point to gaps, inconsistencies, or unsubstantiated claims.
Check the most relevant FDA guidance and standards expectations
Compare your approach against the guidance that applies to your device type and risk profile. Missing elements often reveal the real concern.
Ask: “What is the reviewer trying to rule out?”
Common underlying concerns are patient harm, incorrect performance claims, misuse risk, software failure modes, or an equivalence gap that could change the regulatory pathway.
Use category risk signals, not as mind-reading
Look at MAUDE reports and recalls to understand common failure modes in your category, and use that to strengthen your response narrative and risk rationale. Do not treat MAUDE as definitive proof of causality.
This is where an evidence-linked workspace helps. Complizen keeps your predicate comparisons, standards/guidance excerpts, and risk signals in one place so each deficiency response can point to a source and a rationale, not just a document dump.
Common surface question → underlying concern patterns
Substantial equivalence questions usually mean: “Your differences may matter more than you claim.” FDA wants evidence, not assertions.
Testing questions usually mean: “The evidence may be incomplete, misaligned to expectations, or not clearly tied to your claims.”
Clinical questions usually mean: “Bench evidence alone may not resolve the uncertainty for this device or these differences.”
Device description questions usually mean: “We can’t evaluate equivalence if we don’t understand exactly what the device is and how it works.”
Bottom line: answering the underlying concern doesn’t guarantee clearance, but it can materially reduce back-and-forth and strengthen your review cycle.
The 8 Most Common FDA Additional Information Request Themes
Type 1: Substantial Equivalence (SE) rationale gaps
Why FDA asks
A 510(k) must demonstrate the new device is substantially equivalent to a legally marketed predicate. If the SE argument is unclear or unsupported, FDA can’t complete the review.
What FDA is really concerned about
That technological differences may affect safety or effectiveness, and your submission does not provide enough evidence to rule that out.
Common SE questions (examples)
“Clarify how your device’s [feature] is substantially equivalent given the differences.”
“Provide comparative performance data showing the difference does not affect safety/effectiveness.”
“Explain why clinical data is not needed given [difference].”
How to structure the response
State the difference plainly.
Explain why it does not change intended use or safety/effectiveness.
Provide evidence that directly addresses the reviewer’s concern: comparative testing, literature, risk rationale, and clear linkage to claims.
Common mistakes
Calling a difference “minor” without evidence.
Repeating marketing-level statements (“same purpose”) instead of technical justification.
Switching predicates mid-cycle without an explicit, strategic rationale.
Type 2: Testing evidence and documentation gaps
Why FDA asks
FDA needs enough testing detail to evaluate whether your performance and safety claims are supported, and whether the evidence is appropriate for your device and intended use.
What FDA is really concerned about
That key tests are missing, the testing does not map clearly to claims, or the documentation is not sufficient for FDA to evaluate.
How to structure the response
Build a standards and testing map: what was tested, how it ties to claims, and which recognized standards (if used) support your Declaration of Conformity. The FDA recognized consensus standards database is the source of truth for what FDA recognizes and when.
Provide complete enough protocols/methods, acceptance criteria, results, and rationale so FDA can evaluate.
Common mistakes
Sending summaries when FDA needs full detail to evaluate.
Providing results without acceptance criteria or rationale.
Referencing tests in the narrative but not including the supporting documentation.
Type 3: Unclear or inconsistent device description
Why FDA asks
The 510(k) must provide sufficient detail for FDA to determine substantial equivalence, and the device description is foundational to that determination.
What FDA is really concerned about
That the reviewer can’t reliably compare your device to the predicate because key characteristics are missing, vague, or contradictory across sections.
How to structure the response
Provide quantitative, complete technical characterization.
Eliminate contradictions across device description, Indications for Use, comparison tables, testing, and labeling.
If software is involved, provide documentation consistent with FDA expectations and, where applicable, lifecycle framing such as IEC 62304.
Type 4: Biocompatibility evaluation gaps
Why FDA asks
For patient-contacting devices, FDA expects a biocompatibility evaluation that is appropriate for contact type, contact duration, and risk, often using ISO 10993-1 within a risk management process.
What FDA is really concerned about
That not all patient-contacting materials were evaluated, endpoints do not match the actual contact duration, or the rationale is not defensible for the finished device.
How to structure the response
List all patient-contacting materials, configurations, and the finished (including sterilized) state.
Justify endpoint selection under ISO 10993-1 risk management and FDA guidance.
Where appropriate, include chemical characterization and toxicological assessment, which FDA discusses in its ISO 10993-1 guidance.
Common mistakes
Assuming “biocompatible” materials don’t require evaluation in the specific use scenario.
Relying on supplier data without proving equivalence to your finished device and exposure scenario.
Type 5: Software documentation and cybersecurity gaps
Why FDA asks
FDA needs enough software documentation to assess safety and effectiveness for device software functions, including software in a device and SaMD. FDA’s software guidance describes recommended documentation and encourages the use of FDA-recognized consensus standards, including IEC 62304.
What FDA is really concerned about
That your software lifecycle evidence is incomplete, your V and V does not trace to requirements, cybersecurity is not addressed appropriately for the device, or your software risk classification and safety rationale are not defensible.
Common questions (examples)
“Provide software documentation consistent with FDA’s device software functions guidance, including requirements, architecture, V and V, and traceability.”
“Provide cybersecurity documentation consistent with FDA’s current cybersecurity guidance, including risk management artifacts and SBOM expectations for cyber devices under section 524B.”
How to structure the response
Confirm software risk classification and justify it with a safety rationale.
Provide a clean traceability story, requirements to tests to results.
Provide cybersecurity artifacts aligned to the current FDA guidance, and if your product is a cyber device, ensure the 524B elements are addressed.
Common mistakes
Treating cybersecurity as optional for connected products, or treating SBOM as universal for every device with software. SBOM expectations are tied to cyber device scope under 524B.
Type 6: Clinical evidence adequacy questions
Why FDA asks
When bench and performance evidence does not fully resolve uncertainty for your intended use, claims, or technological differences, FDA may question whether clinical evidence is needed to support substantial equivalence.
What FDA is really concerned about
That your technological differences could affect clinical performance, that literature is not applicable to your device or claims, or that your clinical rationale does not match the risk profile.
How to structure the response
Decide which path is defensible for your case:
Add or strengthen bench and performance evidence, and explain why it resolves the uncertainty.
Provide a systematic literature evaluation and explain applicability to your device, population, and claims.
Provide clinical data, or propose a plan, possibly via Q-Sub if the situation is complex.
Common mistakes
Treating “clinical not required” as a blanket rule.
Sending a few favorable papers without a structured, transparent approach to relevance and quality.
Type 7: Labeling and Instructions for Use issues
Why FDA asks
Labeling must comply with applicable requirements in 21 CFR Part 801 and must be consistent with your Indications for Use, claims, and evidence.
What FDA is really concerned about
That your labeling expands indications beyond what your evidence supports, misses risk communication needed for safe use, or conflicts with your submission narrative.
How to structure the response
Align Indications for Use wording across the submission and labeling.
Ensure warnings, precautions, contraindications, and instructions map to your risk management and evidence.
Remove unsupported performance claims.
Common mistakes
Adding marketing claims that are not supported by testing.
Leaving contradictions between labeling, device description, and performance data.
Type 8: Risk management gaps
Why FDA asks
FDA expects a credible risk management approach that identifies hazards, evaluates risks, and documents controls. ISO 14971 is an FDA-recognized consensus standard that many teams use to structure this.
What FDA is really concerned about
That your hazard analysis misses key hazards, your risk ratings are not defensible, mitigations are unclear, residual risk is not communicated, or your risk controls are not supported by testing and labeling.
How to structure the response
Provide a risk management file update addressing the specific gaps FDA pointed to.
Tie each key hazard to:
controls in design or process,
verification evidence that controls work,
labeling that communicates residual risk.
Common mistakes
Calling risks “negligible” without evidence.
Listing hazards without controls, or controls without verification evidence.
FDA Additional Information Response Strategy: Step-by-Step
Step 1: Break the AI letter into a response map
Read the entire AI letter and split it into discrete questions.
Number each question and tag it by theme: substantial equivalence, testing, device description, biocompatibility, software, clinical, labeling, risk management.
For each item, write the surface ask and the underlying concern, then link it to the exact section of your original submission that triggered it.
Create a tracking sheet with: question number, exact FDA text, owner, evidence required, draft status, and appendix reference.
Step 2: Triage by “impact” not just effort
Sort questions into:
Clarifications (you already have the data, FDA needs clarity or completeness)
Evidence gaps (you need additional testing, analysis, or better documentation)
Strategy risks (FDA is questioning SE logic, intended use alignment, or whether evidence is sufficient)
If an item affects your predicate logic, intended use, or core performance claims, treat it as high priority even if it looks short.
Step 3: Choose a response strategy for each question
For each question, define:
Direct answer (what you will explicitly provide)
Evidence (what documents/data will be attached)
Rationale (why the evidence resolves the concern)
Risk check (what new claims you must avoid)
Recommended response template:
FDA question (quote exactly)
Direct answer (clear, concise)
Supporting evidence (tests, tables, results, methods)
Regulatory rationale (tie evidence to SE, safety, effectiveness)
Appendix references (easy to find)
Step 4: Gather evidence and package it for review speed
Use one appendix numbering system.
Make every appendix self-explanatory with a short cover page: “What this is,” “What it proves,” “Where it’s referenced.”
If evidence is missing, decide fast whether it can realistically be generated within the 180-day window.
Step 5: Draft responses in a reviewer-friendly format
Use Q-and-A format, one question at a time.
Keep tone neutral, factual, and evidence-led.
Avoid new claims or expanded indications unless you are intentionally changing strategy.
Step 6: Run expert and cross-functional review
Minimum checks:
Regulatory: does it fully answer the deficiency and preserve the SE narrative?
Engineering: technical accuracy and consistency with device design
Quality: test documentation completeness, risk management alignment
Clinical (if applicable): claims and clinical interpretation
Step 7: Final assembly and verification
Cover letter summarizing what’s included.
Response document with numbered questions matching FDA’s order.
Appendices with clear labels.
Final QA: every question answered, every reference included, no contradictions introduced.
Step 8: Submit within the 180-day deadline
FDA requires a complete response within 180 calendar days, and FDA states no extensions beyond 180 days are granted. If you cannot provide a complete response in time, you should consider withdrawal and resubmission with a stronger package rather than missing the deadline.
Submit through the same FDA channel used for the original 510(k), commonly eSTAR for eligible submissions.
Response Examples: What Works vs What Doesn’t
Note: The examples below use placeholder 510(k) numbers and simplified test tables for illustration. Always verify real predicates in FDA’s 510(k) database and attach real test reports and methods.
Example 1: Substantial Equivalence question (material difference)
FDA question (example):
“Clarify the substantial equivalence rationale for the use of polyurethane in your device when the predicate uses silicone. Provide comparative performance data demonstrating equivalent biocompatibility and mechanical properties.”
❌ Weak response (what not to do)
“Both polyurethane and silicone are biocompatible materials commonly used in medical devices. We believe they are substantially equivalent for our application.”
Why this fails
Doesn’t provide the comparative evidence FDA asked for
Uses vague assertions instead of data and rationale
Doesn’t address the specific risk: exposure scenario and contact duration under a risk-based biological evaluation
✅ Strong response (what to do)
“The subject device uses medical-grade polyurethane while the predicate uses silicone. We evaluated the finished, patient-contacting materials under an ISO 10993-1 risk-based biological evaluation plan appropriate to the contact type and duration, and we performed comparative bench testing to show the material change does not affect safety or performance.”
Biocompatibility (example structure, not fictional results):
Device categorization (contact type and duration)
Endpoint rationale per ISO 10993-1
Summary table of tests performed, method, acceptance criteria, and outcomes
Appendices with full reports for the subject device and any supporting literature or supplier documentation
Mechanical performance (example structure):
Define which properties matter for safety and function (tensile, tear, fatigue, hardness, etc.)
Provide comparative test methods, acceptance criteria, and results
Explain why any differences do not introduce new risks and are consistent with intended use
Key principle: Don’t rely on “predicate testing reports” you don’t actually have. Use your own testing, plus public predicate summaries and literature only as supportive context.
Example 2: Testing documentation question (biocompatibility package)
FDA question (example):
“Provide complete biocompatibility documentation per ISO 10993-1 for all patient-contacting materials. Your submission references testing but does not include methods, acceptance criteria, or results.”
❌ Weak response
“Biocompatibility testing was completed at an accredited laboratory. All materials passed required tests.”
Why this fails
No protocols, acceptance criteria, or results
No device categorization and endpoint rationale
No traceable appendices
✅ Strong response (what to do)
“Biocompatibility was evaluated using an ISO 10993-1 risk-based biological evaluation plan appropriate to the device’s contact type and duration. We provide the biological evaluation rationale and the complete reports FDA requested in the attached appendices.”
Include (in a clean table):
Patient-contacting materials and configurations (including coatings and adhesives)
Contact type and duration categorization
Endpoints addressed and why
Test method, acceptance criteria justification, results summary
Appendices with complete reports
Important nuance: If your device does not have blood contact, do not imply hemocompatibility is required by default. Tie endpoints to the exposure scenario and risk assessment.
If you include chemical characterization:
Phrase it correctly: FDA may expect chemical characterization, often aligned with ISO 10993-18, especially for novel materials or long-term exposure, and you should explain why it is necessary and how it supports the toxicological risk assessment.
The Fastest Path to Market
Frequently Asked Questions: FDA Additional Information (AI) Requests
1) How long do I have to respond to an FDA Additional Information request?
FDA must receive a complete response within 180 calendar days of the AI Request date. FDA states no extensions beyond 180 days are granted.
2) Can I request an extension on the AI response deadline?
No. FDA states it must receive a complete response within 180 calendar days and no extensions beyond 180 days are granted.
3) What happens if I miss the 180-day deadline?
FDA considers the 510(k) withdrawn and deleted from its review system. To pursue clearance, you must submit a new 510(k).
4) Do I need to pay a new user fee if my submission is withdrawn?
A new 510(k) submission generally requires a new user fee. FDA’s FY2026 510(k) user fee is $26,067 (standard) and $6,517 (small business), and fees change each fiscal year.
5) Can I change my predicate device in my AI response?
It’s possible, but it’s high-risk. If you switch predicates, explain why the original predicate is no longer appropriate and provide a complete substantial equivalence rationale for the new predicate. Expect additional FDA scrutiny.
6) Should I provide more than FDA asked for?
Answer every question completely, but avoid introducing unrelated new claims or issues. Include supporting evidence that directly resolves the reviewer’s concern, without expanding scope unnecessarily.
7) Can AI tools write my entire AI response letter?
AI tools like Complizen can help draft and organize. FDA cares about accuracy and completeness, not how the response was produced.
8) Can I voluntarily withdraw my 510(k) after receiving an AI request?
Yes. Some teams withdraw strategically if the AI request reveals major gaps that cannot be resolved within the 180-day window, then resubmit later with stronger evidence.